Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection: A large-scale multicenter study in China
Guo-Shuang Shen, Jiu-Da Zhao, Jun-Hui Zhao, Xin-Fu Ma, Fa-Xiang Ji, Fang-Chao Zheng, Zi-Yi Wang, Affiliated Hospital of Qinghai University, High Altitude Medical Research Center, Xining 810001, Qinghai Province, China
Jiu-Da Zhao, Feng Du, Fei Ma, Bing-He Xu, Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Jie Kan, People’s Hospital of Qinghai Province, Xining 810007, Qinghai Province, China
Author contributions: Shen GS and Zhao JD contributed equally to this work; Shen GS, Zhao JD and Xu BH designed the research; Zhao JH, Ma XF, Du F, Kan J, Ji FX, Zheng FC and Wang ZY performed the research; Kan J and Ji FX contributed new reagents/analytic tools; Shen GS and Zhao JD analyzed the data and wrote the paper.
Supported by National Natural Science Foundation of China, No. 81360318; and the Application and Basic Research Program of Qinghai Province of China, No. 2014-Z-745.
Institutional review board statement: The study was reviewed and approved by the Qinghai University Affiliated Hospital and National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical Colleg Institutional Review Board.
Informed consent statement: Informed consent was obtained from all individual participants for whom identifying is included in this article prior to study enrollment.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: Technical appendix, statistical code, and dataset available from the coauthor at email@example.com. Participants gave informed consent for data sharing.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Bing-He Xu, MD, Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. firstname.lastname@example.org
Telephone: +86-10-87788826 Fax: +86-10-8771 5711
Received: January 10, 2016
Peer-review started: January 22, 2016
First decision: February 14, 2016
Revised: May 11, 2016
Accepted: May 21, 2016
Article in press: May 23, 2016
Published online: June 21, 2016